Physician profile
Michael S Jaffe
NPI 1396893251
$12,359.58
in general payments reported to CMS, 2019-2025
25 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $747 · 2021: $1,173 · 2022: $1,563 · 2023: $3,319 · 2024: $1,878 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,092 · Travel and Lodging: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,092.17 |
| Travel and Lodging | $1,949.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,984.74 | 2021-2025 | Synchromedii, Percept PC Brainsense, Inceptiv |
| Abbott Laboratories | $2,102.30 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,697.52 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Coveredge 32 |
| Abbvie INC. | $1,129.10 | 2021-2025 | |
| Medtronic USA, INC. | $970.52 | 2019-2020 | |
| Nevro Corp. | $605.34 | 2022-2023 | Senza |
| Allergan, INC. | $508.27 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $374.48 | 2021-2024 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $275.45 | 2019-2025 | Dysport |
| Vertex Pharmaceuticals Incorporated | $255.65 | 2025 | |
| Mml US, INC. | $222.14 | 2025 | Reactiv8 |
| Amgen INC. | $164.41 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Biotronik Nro, INC. | $163.69 | 2024 | Prospera |
| Merz North America, INC. | $149.40 | 2019-2020 | |
| Relievant Medsystems, INC. | $136.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $113.53 | 2019 | |
| Spr Therapeutics, INC | $93.00 | 2025 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $87.74 | 2023 | Iovera, Zilretta |
| Pfizer INC. | $84.44 | 2019-2025 | |
| Pacira Therapeutics, INC. | $80.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $67.28 | 2025 | Ponvory |
| Kowa Pharmaceuticals America, INC. | $28.30 | 2023 | Seglentis, Livalo |
| Livanova USA, INC. | $26.99 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Avanos Medical | $19.67 | 2024 | Genvisc 850 Sodium Hyaluronate |
| Stryker Corporation | $19.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.